News


Health Innovation KSS welcomes new Chief Commercial Officer

Health Innovation KSS welcomes new Chief Commercial Officer
News

Health Innovation Kent Surrey Sussex (KSS) has appointed Chris Hill as Chief Commercial Officer, joining the executive management group to support the organisation through a period of exciting growth.

With 17 years of experience at Sanofi, Chris brings extensive pharmaceutical and healthcare expertise to the role. His career at Sanofi included several senior positions in both UK and global operations, serving as Divisional Finance Director, Chief of Staff to the General Manager, and most recently as Global Portfolio Operations Lead. Throughout his career, Chris has developed strong relationships with key stakeholders across the Department of Health and Social Care and NHS England.

Professor Hatim Abdulhussein, CEO of Health Innovation KSS, welcomed the appointment: “We are excited to welcome Chris to our team to support us to achieve our ambitions for the future. His wealth of experience from the life sciences and commercial sector will be invaluable in building partnerships with wider stakeholders to drive innovation addressing national and regional priorities. This appointment reinforces our commitment to driving a healthier and more equitable society by rapidly spreading innovation and connecting people to transformative ideas.”

Set to begin his role in March, Chris will spearhead the organisation’s expansion of strategic partnerships and business development initiatives. He will focus on developing bespoke projects that complement existing national and local commissions while addressing specific regional healthcare needs, as outlined in the organisation’s 2024-2026 business plan.

Chris said: “As we navigate an exciting period of growth, I am thrilled to join Health Innovation KSS and collaborate with partners across the healthcare ecosystem. Together, we have a unique opportunity to accelerate innovation, drive meaningful change and improve health outcomes for communities across Kent, Surrey, and Sussex.”

Related news

Elekta Unity combines magnetic resonance imaging (MRI) with a medical linear accelerator (linac) to improve precision radiotherapy for cancer, potentially reducing treatment burden for patients while improving outcomes.

Case StudyNews

12 Mar 2025

More

MUTU®, the evidence-based digital postnatal recovery platform, has secured its first NHS contract. The programme will be implemented in Medway...

News

19 Feb 2025

More

NHS Sussex has partnered with Health Innovation Kent Surrey Sussex (KSS) to support scoping and evaluation of an employment support programme aimed at helping individuals facing health-related barriers get back into work.

News

19 Feb 2025

More

Elekta Unity combines magnetic resonance imaging (MRI) with a medical linear accelerator (linac) to improve precision radiotherapy for cancer, potentially reducing treatment burden for patients while improving outcomes.

Case StudyNews

12 Mar 2025

More

MUTU®, the evidence-based digital postnatal recovery platform, has secured its first NHS contract. The programme will be implemented in Medway...

News

19 Feb 2025

More

NHS Sussex has partnered with Health Innovation Kent Surrey Sussex (KSS) to support scoping and evaluation of an employment support programme aimed at helping individuals facing health-related barriers get back into work.

News

19 Feb 2025

More